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Abstract
Background: We have previously reported that expression of the RNA- and DNA-binding protein RBM3 is
associated with a good prognosis in breast cancer and ovarian cancer. In this study, the prognostic value of
immunohistochemical RBM3 expression was assessed in incident cases of malignant melanoma from a prospective
population-based cohort study.
Methods: Until Dec 31
st 2008, 264 incident cases of primary invasive melanoma had been registered in the Malmö
Diet and Cancer Study. Histopathological and clinical information was obtained for available cases and tissue
microarrays (TMAs) constructed from 226 (85.6%) suitable paraffin-embedded tumours and 31 metastases. RBM3
expression was analysed by immunohistochemistry on the TMAs and a subset of full-face sections. Chi-square and
Mann-Whitney U tests were used for comparison of RBM3 expression and relevant clinicopathological
characteristics. Kaplan Meier analysis and Cox proportional hazards modelling were used to assess the relationship
between RBM3 and recurrence free survival (RFS) and overall survival (OS).
Results: RBM3 could be assessed in 215/226 (95.1%) of primary tumours and all metastases. Longitudinal analysis
revealed that 16/31 (51.6%) of metastases lacked RBM3 expression, in contrast to the primary tumours in which RBM3 was
absent in 3/215 (1.4%) cases and strongly expressed in 120/215 (55.8%) cases. Strong nuclear RBM3 expression in the
primary tumour was significantly associated with favourable clinicopathological parameters; i.e. non-ulcerated tumours,
lower depth of invasion, lower Clark level, less advanced clinical stage, low mitotic activity and non-nodular histological
type, and a prolonged RFS (RR = 0.50; 95% CI = 0.27-0.91) and OS (RR = 0.36, 95%CI = 0.20-0.64). Multivariate analysis
demonstrated that the beneficial prognostic value of RBM3 remained significant for OS (RR = 0.33; 95%CI = 0.18-0.61).
Conclusions: In line with previous in vitro data, we here show that RBM3 is down-regulated in metastatic melanoma
and high nuclear RBM3 expression in the primary tumour is an independent marker of a prolonged OS. The potential
utility of RBM3 in treatment stratification of patients with melanoma should be pursued in future studies.
Background
Malignant melanoma is an aggressive form of cancer
with a variable clinical course even in patients with thin
melanomas and localized disease [1-4]. Despite increas-
ing insights into melanoma biology and the discovery of
gene- and protein-signatures that supplement
established prognostic clinicopathological parameters
[5-7], no biomarkers have yet been incorporated into
clinical protocols.
The RNA-binding motif protein 3, RBM3, was initially
identified in a human fetal brain tissue cDNA library
[8]. The RBM3 gene maps to Xp11.23 and encodes two
alternatively spliced RNA transcripts. RBM3 transcripts
have been found in various human tissues [8] and in
vitro, RBM3 is one of the earliest proteins synthesized
in response to cold shock [9]. RBM3 contains one RNA-
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DNA and RNA, whereby a glycine rich region adjacent
to the RNA binding motif is thought to enhance the
protein-RNA or protein-DNA interaction [8,10].
B a s e do na ni n i t i a ld i s c o v e r yi nt h eH u m a nP r o t e i n
Atlas (HPA) http://www.proteinatlas.org[11-13], we have
recently demonstrated that tumour-specific expression
of RBM3, in particular its nuclear localization, is asso-
ciated with a significantly improved survival in breast
cancer [14] and ovarian cancer [15], and that RBM3
confers cisplatin sensitivity in ovarian cancer cells [15].
Apart from these studies, we are not aware of any other
publications related to the prognostic or treatment pre-
dictive impact of the tumour-specific expression of
RBM3 in human cancer, and the biological processes
underlying these observations have not yet been unra-
veled. It is evident that RBM3 is up-regulated in various
types of human malignancies [14,16,17] and in vitro stu-
dies in a wide range of different model systems have
demonstrated that RBM3 is involved in multiple pro-
cesses central to cancer biology, like proliferation
[15-17], apoptosis [18,19] and angiogenesis [16].
The prognostic value of RBM3 expression has, to our
knowledge, not yet been investigated in malignant mela-
noma. However, down-regulation of RBM3 at the gene
expression level has been demonstrated in an in vitro
model of melanoma progression [20].
In the present study, we investigated the prognostic
impact of immunohistochemical (IHC) RBM3 expres-
sion in 215 incident malignant melanomas in the pro-
spective, population-based cohort Malmö Diet and
Cancer Study (MDCS) [21]. For this purpose, tissue
microarrays (TMAs) were constructed from suitable
tumours (n = 226) and a subset of metastases (n = 31).
It is demonstrated that strong nuclear expression of
RBM3 correlates with favourable clinicopathological
parameters and independently predicts a significantly
prolonged overall survival. In addition, a markedly
reduced expression of RBM3 was observed in metastases
compared to primary tumours, which is quite in line
with previous in vitro data [20].
Methods
The Malmö Diet and Cancer Study
The Malmö Diet and Cancer Study (MDCS) is a popula-
tion-based prospective cohort study with the main aim
to examine whether a Western diet rich in fat and low
in fruit and vegetables increases the risk of certain
forms of cancer. Between 1991-1996, a total number of
28 098 individuals; 11 063 (39,4%) men and 17 035
(60,6%) women between 44-74 years where enrolled
(from a background population of 74 138). All partici-
pants completed the baseline examination, which
included a questionnaire, measures of anthropometric/
body compositions and a dietary assessment. The ques-
tionnaire covered questions on physical activity, use of
tobacco and alcohol, heredity, socio-economic factors,
education, occupation, previous and current disease and
current medication. In addition, blood samples were col-
lected and stored in -80°C. Follow up is done annually
by record-linkage to national registries for cancer and
cause of death [22].
Ethical permissions for the MDCS (Ref. 51/90) and the
present study (Ref. 530/2008) were obtained from the
Ethical Committee at Lund University.
Incident malignant melanomas until Dec 31
st 2008
Until end of follow-up 31 December 2008, 264 incident
invasive malignant melanomas had been registered in
the study population. Cases were identified from the
Swedish Cancer Registry up until 31 Dec 2007, and
from The Southern Swedish Regional Tumour Registry
for the period of 1 Jan-31 Dec 2008. All tumours with
available slides and/or paraffin blocks were histopatholo-
gically re-evaluated on haematoxylin and eosin stained
slides whereby information on lymphocytic infiltration
(none, mild, moderate or high), ulceration (absent or
present), mitotic count and vascular invasion was
obtained. Data on location, Clark level and Breslow
depth of invasion was obtained from the clinical- and/or
pathology records.
Information on recurrence (local, regional or distant)
was obtained in 2010 from patient records and pathol-
ogy reports. Information on vital status and cause of
death was obtained from the Swedish Cause of Death
Registry up until 31 Dec 2009.
Tissue microarray construction
Paraffin-embedded tumour specimens were collected
from the archives of the pathology departments in the
region of Skåne in Southern Sweden. Tumours with an
insufficient amount of material were excluded. Areas
representative of cancer were then marked on haema-
toxylin & eosin stained slides and TMAs constructed as
previously described [23]. In brief, three 0,6 mm cores
were taken from each tumour and mounted in a new
recipient block using semi-automated arraying device
(TMArrayer, Pathology Devices, Westminster, MD,
USA). In addition, metastases (representing both regio-
nal and distant metastases in various organs) were
sampled from 31 cases. Thin melanomas (< 1 mm) were
subjected to TMA construction if the diameter was > 1
cm. To check for heterogeneity, IHC staining was also
performed on additional full-face sections from 25 cases.
Immunohistochemistry and evaluation of RBM3 staining
For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT-link system
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Autostainer Plus (DAKO, Glostrup, Denmark) with the
mouse monoclonal anti-RBM3 antibody (AAb030038;
Atlas Antibodies AB, Stockholm, Sweden, diluted
1:5000). The specificity of the antibody has been vali-
dated previously [15].
As RBM3, when present, was expressed in > 75% of
the cells, predominantly in the nuclei and in varying
intensities, only the intensity of the staining was
accounted for and denoted a score from 0 (negative), 1
(mild), 2 (moderate) and 3 (strong). The staining was
evaluated by three independent observers (LJ, JB, and
BN) who were blinded to clinical and outcome data.
Scoring differences were discussed in order to reach
consensus.
Statistical analysis
Chi-square and Mann-Whitney U tests were used for
comparison of RBM3 expression and relevant clinico-
pathological characteristics. Recurrence was defined as
local, regional or distant recurrence or death from
malignant melanoma and risk of recurrent disease was
referred to as recurrence free survival (RFS). Follow-up
started at date of diagnosis and ended at recurrent dis-
ease, death, lost to follow-up (emigration) or last date of
follow- up with regard to recurrent disease. No recur-
rences were recorded following the last date of follow-
up regarding death, i.e. 31 Dec 2009. Overall survival
(OS) was assessed by calculating the risk of death from
all causes, overall mortality. Follow-up started at date of
diagnosis and ended at death, emigration or 31 Dec
2009, whichever came first.
Kaplan-Meier analysis and log rank test were used to
illustrate differences in RFS and OS. Cox regression pro-
portional hazards models were used to estimate the
impact of the investigated parameters on RFS and OS in
both uni- and multivariate analysis. Some subjects had
no information on one or several markers and missing
values were coded as a separate category for categorical
variables and as the mean of all observations for contin-
uous variables. Missing values for categorical variables
co-varied and the multivariate model did not converge
due to many constant values. In order to avoid this, the
multivariate analysis only included patients with infor-
mation on RBM3. In addition, the patient with missing
information on lymphocytic infiltration had to be
excluded. Co-variates were entered into the multivariate
analysis using backward selection were a p-value of 0.05
decided entry and a p-value of 0.20 was used for
removal. RBM3 was included in all models irrespective
of the backward selection procedure.
All tests were two sided. A p-value of 0.05 was consid-
ered significant. All statistical analyses were performed
using SPSS version 17 (SPSS Inc, Chicago, IL).
REMARK criteria
A description of the fulfilment of REMARK [24] criteria
for biomarker studies is provided in Additional file 1,
Table S1.
Results
Distribution of clinicopathological parameters in the
cohort
The distribution of patient- and tumour characteristics
in the full cohort is shown in Table 1. In line with the
relatively high median age of cases (69 years, range 44-
85), the frequency of lentigo maligna melanomas was
slightly higher (11.7%) than the average expected around
7% in Sweden [2]. The proportion of thinner melanomas
(< = 1 mm, Stages 1A-B) was also higher than expected
(86.5% compared to ~55.1%) as well as the proportion
of non-ulcerated tumours (14.1% compared to ~24.1%)
[2].
Immunohistochemical expression of RBM3 in primary
tumours and metastases
Of the 226 cases in the TMA cohort it was possible to
evaluate the expression of RBM3 protein in 215 cases
(95,1%). There was no obvious heterogeneity in the
staining pattern between the tissue cores. There was an
excellent concordance between RBM3 scores assessed
on full-face sections and TMAs (kappa-value 0.85).
Examples of immunohistochemical staining are shown
in Figure 1A-D and the staining distribution in primary
tumours vs metastases in Figure 1E-F. Interestingly, and
in line with previous in vitro data [20], RBM3 expres-
sion was strong in the majority of primary tumours, but
weak or absent in the metastases (Figure 1E-F). Notably,
similar associations were seen when comparing primary
tumours and metastases in the 31 cases, for which both
locations had been sampled (data not shown).
Association between RBM3 expression and
clinicopathological parameters
As shown in Table 2, there was a strong association
between low RBM3 expression and depth of invasion,
Clark level, clinical stage, mitotic count, nodular vs non-
nodular type and ulceration. However, localization, age,
lymphocytic infiltration and melanoma type were not
associated with RBM3 expression. In some cases with
strong RBM3 expression, cytoplasmic staining was pre-
sent in various intensities, but this did not add any
prognostic value (data not shown).
Impact of high RBM3 expression on recurrence free
survival and overall survival
Having demonstrated that RBM3 is associated with less
advanced disease and favourable clinicopathological
parameters, the relationship between RBM3 expression
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sis, data were dichotomized into strong vs negative-
moderate intensity for RBM3.
Kaplan Meier analysis of the evaluated cohort (n =
215) demonstrated that high expression of RBM3 was
Table 1 Patient and tumour characteristics in the full
cohort (n = 264)
Age
Mean 67.29
Median 69.00
Range 46-84
Sex
Female 135 (51.1%)
Male 129 (48.9%)
Location
Head and neck 17 (14.9%)
Extremities 111 (44.8%)
Dorsal thorax 65 (26.2%)
Frontal thorax 35 (14.1%)
Unknown 16
Clark level
II 93 (37.7%)
III 103 (41.7%)
IV 44 (17.8%)
V 7 (2.8%)
Unknown 17
Breslow (mm)
Mean 1.57
Median 0.71
Range 0.08-40.00
Breslow AJCC categories
< = 1 158 (59.8%)
1-2 36 (13.6%)
2-4 40 (15.2%)
> 4 14 (5.3%)
Unknown 16 (6.1%)
Clinical Stage
1A 154 (74.4%)
1B 25 (12.1%)
2A 17 (8.2%)
2B 7 (3.4%)
3A 2 (1.0%)
4 2 (1.0%)
Unknown 57
Histological type
SSM 160 (64.5%)
NMM 53 (21.48%)
LMM 29 (11.7%)
Other 6 (2.4%)
Unknown 16
Ulceration
Absent 214 (85.9%)
Present 35 (14.%)
Unknown 16
Mitotic count
< 1/mm
2 131(51.8)
> = 1/mm
2 122(46.2)
Lymphocytic infiltration
None-mild 72 (29.0%)
Figure 1 RBM3 expression in primary melanomas and
metastases. Examples of malignant melanomas with (A) negative,
(B) weak, (C) intermediate and (D) strong immunohistochemical
RBM3 staining. RBM3 expression was strong in the majority of (E)
primary tumours compared to (F) metastases.
Table 1 Patient and tumour characteristics in the full
cohort (n = 264) (Continued)
Moderate-high 176 (66.7%)
Unknown 16
Recurrence
No 217 (82.2%)
Yes 47 (17.8%)
Follow-up (years)
Mean 7.25
Median 6.88
Range 0.64-17.05
Vital status
Dead 55 (20,8%)
Alive 219 (79,2%)
Dead from malignant melanoma 28 (10.6%)
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and OS (p < 0.001) (Figure 2). In Cox multivariate ana-
lysis, high RBM3 expression remained an independent
prognostic parameter for OS but not RFS (Table 3).
In thin melanomas (< = 1 mm; n = 129) there was no
significant association between RBM3 expression and
RFS (data not shown) and a trend, however non-signifi-
cant, towards a prolonged OS for tumours with high
RBM3 expression (RR = 0.48; 95%CI = 0.18-1.24). In
melanomas > 1 mm (n = 84), RBM3 was not associated
with RFS (data not shown) but with a significantly
improved OS (RR = 0.40; 95% CI = 0.19-0.85), which
remained significant in multivariate analysis (RR = 0.29;
95% CI = 0.11-0.77). Notably, tumour thickness mea-
sured as a continuous variable did not remain significant
in multivariate analysis. However, this was not altered
when AJCC categories (< 1 mm, 1-2 mm, 2-4 mm and
> 4 mm) were used instead or when clinical stage was
excluded from the analysis (data not shown).
Information on tumour diameter was only available
for 162 (61%) of the patients and therefore not included
in the analyses. There was an inverse association
between tumour diameter and RBM3 expression (p =
0.030) but not to depth of invasion (data not shown).
There was no association between tumour diameter and
survival (data not shown)
Discussion
This study provides a first description of the patient and
tumour characteristics of incident cases of malignant
melanoma in the prospective, population-based cohort
Malmö Diet and Cancer Study, diagnosed until Dec 31
st,
2008. In addition, it is demonstrated that the investiga-
tive biomarker RBM3 is down-regulated in metastatic
deposits, associated with favourable histopathological
parameters in primary melanomas and an independent
predictor of a prolonged overall survival. In a transla-
tional context, these findings are quite in line with a
Table 2 Association between RBM3 expression and
clinicopathological parameters
RBM3 staining intensity
0-2 3
n(%) 95 (44.2) 120 (55.8) p-value
Age
Mean 68.00 67.15 0.673
(range) (47-83) (46-81)
Gender
Female 45(47.4) 63(52.5) 0.457
Male 50(52.6) 57(47.5)
Clark level
II 21(22.3) 50(42.4) 0.005**
IIII 48(51.1) 46(39.0)
IV-V 25(26.6) 22(18.6)
missing 1 2
Breslow(mm)
Mean 2.47 1.12 0.001**
(range) (0.08-40.00) (0.11-7.00)
Ulceration
No 71(74.7) 109(91.6) 0.001**
Yes 24(25.3) 10(8.4)
missing 0 1
Lymphocytic
infiltrate
0-1 26(27.4) 34(28.6) 0.846
2-3 69(72.6) 85(71.4)
missing 0 1
Clinical stage
I 54(76.1) 95(91.3) 0.005*
II-IV 17(23.9) 9(8.7)
missing 24 16
Vascular invasion
No 87(91.6) 114(95.0) 0.314
Yes 8(8.4) 6(5.0)
Localization
Head and neck 15(16.0) 16(14.0) 0.352
Extremities 40(42.6) 59(51.8)
Frontal thorax 10(10.6) 15(13.2)
Dorsal thorax 29(30.9) 24(21.1)
missing 1 6
Type
SSM, LMM, Other 65(58.9) 97(68.9) 0.027*
Table 2 Association between RBM3 expression and clini-
copathological parameters (Continued)
NMM 30(31.6) 22(18.5)
missing 0 1
Mitotic count
< 1/mm
2 34(35.8) 71(59.2) 0.001**
> = 1/mm
2 61(64.2) 49(40.8)
*Significant at the 0.05 level
** Significant at the 0.01 level
§ Mann Whitney U test for comparison of means
SSM = Superficial spreading melanoma
NMM = Nodular malignant melanoma
LMM = Lentigo malignant melanoma
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one of five down-regulated genes in an in vitro model of
melanoma progression [20]. Moreover, as RBM3 has
been demonstrated to be a good prognostic biomarker
in several other cancer forms, e.g. breast cancer [14] and
ovarian cancer [15], its clinical utility in stratification of
melanoma patients should be validated in future studies.
According to current clinical guidelines in Sweden,
sentinel node biopsy is performed in melanomas > 1
mm, but as an increase in thin melanomas (< = 1 mm)
seems to make up for most of the increasing incidence
of malignant melanomas [25], there is an unmet need
for prognostic biomarkers in this category [26]. In this
study, RBM3 was not significantly associated with prog-
nosis in thin (< = 1 mm) melanomas but was an inde-
pendent favourable prognostic factor for OS in
melanomas > 1 mm. The reason for this remains
unclear and further studies in larger patient cohorts are
needed to determine the prognostic value of RBM3 in
thin melanomas. However, the observation that RBM3
remained an independent factor for overall survival in
the cohort as a whole, which represented tumours of
less advanced clinical stages than in the average popula-
tion [2], indicates its potential utility as a biomarker for
prognostic stratification of patients with early-stage
melanoma.
In the light of the above, a methodological aspect that
needs further attention is the bias related to the use of
the TMA technique in malignant melanoma biomarker
studies, e.g. the technical difficulty in sampling small
tumours. In this study, we attempted to sample melano-
mas < 0.5 mm if the diameter was > 10 mm, and in sev-
eral cases, sampling was successful. The mean Breslow
depth of invasion in the TMA cohort was only slightly
higher than in the full cohort (1.66 mm compared to
1.57 mm). In addition, as determined by comparison
with full-face sections for a subset of the tumours,
RBM3 did not seem to display a heterogeneous expres-
sion pattern.
In this study we used a monoclonal antibody against
RBM3, which was also used in our previous study on
ovarian cancer [15]. In the first paper, describing the
prognostic value of RBM3 in breast cancer, we used a
polyclonal antibody generated within the HPA project
[14]. Both antibodies have been extensively validated
using siRNA techniques in breast cancer cell lines [14]
and ovarian cancer cell lines [15] and similar results
have been obtained regarding the staining distribution
in various normal and cancerous tissues (data not
shown). Although being a semi-quantitative method,
IHC has several advantages since it allows for assess-
ment of protein expression in different sub-cellular
compartments, which might have important prognostic
implications. In the case of RBM3, previous findings
indicate that its nuclear rather than cytoplasmic localiza-
tion is the most relevant parameter for prognostication
[14,15], which is also demonstrated here for melanoma.
As the MDCS is a population-based cohort study, a
potential selection bias compared to the general popula-
tion must be taken into consideration [22]. Since all par-
ticipants were > 40 years at study entry, the mean age
among melanoma cases was higher than in the average
population. Notably, since older melanoma patients
often present with more advanced disease [27], the rela-
tively low proportion of cases with advanced disease
reported here is somewhat unexpected. This could in
part be explained by the fact that data necessary for sta-
ging could not be obtained for all cases. Nevertheless,
clinical stage, as well as the prognostic impact of other
established clinicopathological characteristics fell out as
expected, which validates the cohort as a platform for
Figure 2 Prognostic value of RBM3 expression in primary
melanoma. Tumours with high (strong intensity) RBM3 expression
had a significantly improved (A) recurrence free survival and (B)
overall survival compared to tumours with low RBM3 expression
(negative to moderate intensity).
Jonsson et al. Journal of Translational Medicine 2011, 9:114
http://www.translational-medicine.com/content/9/1/114
Page 6 of 9Table 3 Relative risks of recurrence and death according to clinicopathological parameters and RBM3 expression
Relative risk of recurrence Relative risk of death
Univariate Multivariate Univariate Multivariate
n(events) RR(95%CI) RR(95%CI) n(events) RR(95%CI) RR(95%CI)
Age
Continuous 255(47) 1.01(0.97-1.05) 255(53) 1.09(1.04-1.13) 1.07(1.02-1.12)
Gender
Female 132(21) 1.00 132(18) 1.00 1.00
Male 123(26) 1.51(0.85-2.69) 2.60(1.47-4.61) 2.37(1.22-4.57)
Clark level
II 93(5) 1.00 1.00 93(13) 1.00
III 103(21) 4.39(1.65-11.65) 1.93(0.51-7.26) 103(21) 1.70(0.85-3.40)
IV-V 51(21) 9.99(3.76-26.55) 1.02(0.24-4.34) 51(18) 3.04(1.49-6.22)
Breslow
Continuous 248(47) 1.07(1.03-1.11) 248(53) 1.07(1.03-1.12)
Subtype
SSM, LMM, Other 195(22) 1.00 195(30) 1.00 1.00
Nodular 53(24) 5.63(3.15-10.08) 53(22) 3.86(2.21-6.74) 2.32(1.20-4.94)
Ulceration
No 213(30) 1.00 214(35) 1.00 1.00
Yes 35(16) 5.80(3.12-10.77) 35(17) 6.29(3.46-11.45) 3.52(1.63-7.61)
Lymphocytic
infiltrate
0-1 72(20) 1.00 72(22) 1.00 1.00
2-3 176(76) 0.43(0.24-0.78) 176(30) 0.46(0.26-0.79) 0.55(0.30-1.00)
Clinical stage
I 179(12) 1.00 1.00 179(22) 1.00
II-IV 28(13) 15.02(6.39-35.30) 7.36(2.47-21.47) 28(11) 6.48(3.05-13.73)
Mitotic count
< 1/mm
2 131(7) 1.00 1.00 131(17) 1.00
> = 1/mm
2 122(40) 7.99(3.56-17.80) 2.86(0.96-8.47) 122(36) 1.26(1.19-1.34)
Vascular invasion
No 232(35) 1.00 1.00 232(42) 1.00 1.00
Yes 14(11) 9.25(4.67-18.35) 3.40(1.60-7.20) 14(9) 4.88(2.37-10.08) 3.81(1.62-8.97)
RBM3 intensity
0-2 95(24) 1.00 1.00 95(29) 1.00 1.00
3 120(20) 0.50 (0.27-0.91) 0.87(0.46-1.66) 120(20) 0.36(0.20-0.64) 0.33(0.18-0.61)
The number of cases in the multivariate analysis is equal to the number of cases evaluated for RBM3 expression (n = 215).
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to melanoma risk and prognosis.
Given the previously demonstrated association
between RBM3 and cisplatin sensitivity in ovarian can-
cer cell lines [15], the potential value of RBM3 as a pre-
dictor of response to platinum-based chemotherapy in
patients with metastatic malignant melanoma could be
of interest to investigate in future studies. However, in
contrast to the situation in ovarian cancer, where RBM3
showed a consistent expression pattern in primary
tumours and omental deposits [15], the data presented
here, and previous in vitro data [20], show that RBM3 is
down-regulated in the majority of metastatic melano-
mas. Hence, in the predictive setting in melanoma
patients, thorough sampling and immunohistochemical
analysis of metastatic deposits would be required in
order to identify a comparatively small number of
patients with RBM3 positive metastases.
Conclusions
We have demonstrated that the RNA- and DNA-bind-
ing protein RBM3 is an independent biomarker of a
prolonged OS in patients with primary malignant mela-
noma and that RBM3 expression is lost during progres-
sion of the disease. The potential utility of RBM3 in risk
stratification of patients with melanoma should be pur-
sued in future studies.
Additional material
Additional file 1: Supplementary Table 1. Fulfilment of REMARK
criteria [24].
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